Atossa Genetics (NASDAQ:ATOS) Sets New 1-Year Low – What’s Next?

Atossa Genetics Inc. (NASDAQ:ATOS) shares reached a new 52-week low during mid-day trading on Monday . The stock traded as low as $6.17 and last traded at $6.35, with a volume of 234983 shares traded. The stock had previously closed at $8.4750.

Wall Street Analyst Weigh In

Several research firms recently weighed in on ATOS. Ascendiant Capital Markets upped their price objective on shares of Atossa Genetics from $116.25 to $120.00 and gave the stock a “buy” rating in a research report on Monday, December 8th. Zacks Research cut shares of Atossa Genetics from a “hold” rating to a “strong sell” rating in a research report on Monday, October 13th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Atossa Genetics in a research report on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have issued a Sell rating to the company. According to MarketBeat, Atossa Genetics currently has an average rating of “Hold” and a consensus price target of $95.00.

Atossa Genetics Stock Performance

The business has a fifty day simple moving average of $9.98 and a 200-day simple moving average of $11.79. The firm has a market cap of $45.60 million, a price-to-earnings ratio of -1.47 and a beta of 1.36.

Atossa Genetics (NASDAQ:ATOS) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($1.05) earnings per share for the quarter, hitting the consensus estimate of ($1.05). On average, equities analysts anticipate that Atossa Genetics Inc. will post -0.22 earnings per share for the current year.

Hedge Funds Weigh In On Atossa Genetics

A number of hedge funds have recently modified their holdings of the business. Hudson Bay Capital Management LP acquired a new stake in Atossa Genetics in the second quarter valued at $26,000. Gallagher Capital Advisors LLC bought a new stake in shares of Atossa Genetics in the 3rd quarter valued at about $27,000. JPMorgan Chase & Co. increased its stake in shares of Atossa Genetics by 1,294.2% in the third quarter. JPMorgan Chase & Co. now owns 38,215 shares of the company’s stock valued at $33,000 after buying an additional 35,474 shares during the period. Catalyst Funds Management Pty Ltd bought a new position in shares of Atossa Genetics during the second quarter worth about $49,000. Finally, Bank of America Corp DE raised its position in shares of Atossa Genetics by 55.7% during the second quarter. Bank of America Corp DE now owns 99,601 shares of the company’s stock worth $83,000 after acquiring an additional 35,629 shares during the last quarter. Institutional investors and hedge funds own 12.74% of the company’s stock.

Atossa Genetics Company Profile

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.